


Abbott India Limited
271, Business Park, 6th Floor,
Model Industrial Colony,
Off Aarey Road, Goregaon (E)
Mumbai 400063

Registered Office:
3-4, Corporate Park,
Sion Trombay Road,
Mumbai 400 071, India

Tel : (91-22) 2871 7462
Fax : (91 22) 2871 7499
E-mail : webmaster@abbott.co.in
Site : www.abbott.co.in
CIN : L24239MH1944PLC007330



BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

August 26, 2016

Scrip Code: 500488

Dear Sir,

Sub: Intimation under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015


Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a text of Unaudited Financial Results of the Company for the first quarter ended on June 30, 2016, approved by the Board of Directors at its Meeting held on Friday, August 26, 2016, along with the Limited Review Report issued by S R B C & CO. LLP, Statutory Auditors of the Company.

The Meeting of the Board of Directors of the Company commenced at 10.45 am and concluded at 11.30 am.

Kindly acknowledge the receipt of the same.

Thank you.

Yours faithfully,
Abbott India Limited


Krupa Anandpara
Company Secretary
Membership No.: ACS 16536

Encl: a/a

Limited Review Report**Review Report to
The Board of Directors
Abbott India Limited**

We have reviewed the accompanying statement of unaudited financial results of Abbott India Limited ('the Company') for the quarter ended June 30, 2016 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.


Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP
ICAI Firm registration number: 324982E/E300003
Chartered Accountants

per Ravi Bansal
Partner
Membership No.: 49365



Place: Mumbai
Date: August 26, 2016



Statement of Unaudited Results for the Quarter Ended June 30, 2016

(Rs. in Lakhs except earnings per share)

	Particulars	Quarter ended	Quarter ended
		June 30, 2016	June 30, 2015
		Unaudited	Unaudited
1	Income from Operations		
	(a) Sales (Inclusive of Excise Duty)	731,33	630,74
	(b) Other Operating Income	6,79	6,52
	Total Income from Operations	738,12	637,26
2	Expenses		
	(a) Cost of Materials Consumed	71,85	81,20
	(b) Purchase of Stock-in-Trade	365,92	212,97
	(c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(18,37)	65,90
	(d) Employee Benefits Expense	85,81	85,83
	(e) Depreciation and Amortization Expense	4,16	3,36
	(f) Other Expenses	127,51	96,85
	Total Expenses	636,88	546,11
3	Profit from operations before Other Income, Finance Costs (1-2)	101,24	91,15
4	Other Income	13,94	12,52
5	Profit before Finance Costs (3+4)	115,18	103,67
6	Finance Costs	2	3
7	Profit before tax (5-6)	115,16	103,64
8	Tax Expense	41,15	36,33
9	Net Profit for the Period (7-8)	74,01	67,31
10	Other Comprehensive Income (after Tax)		
	- Items that will not be classified to Profit or Loss	-	(25)
	- Items that will be classified to Profit or Loss	-	-
	Total Other Comprehensive income (after Tax)	-	(25)
11	Total Comprehensive Income for the period (9+10)	74,01	67,06
12	Paid-up Equity Share Capital (Face Value Rs.10 per Equity Share)	21,25	21,25
13	Earnings Per Share (EPS) (of Rs. 10/- each) (not annualised):		
	a. Basic	34.83	31.56
	b. Diluted	34.83	31.56

SIGNED FOR IDENTIFICATION
BY 
S R B C & CO LLP
MUMBAI

Notes :


- 1 The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their meeting held on August 26, 2016.
- 2 The Company operates in single reportable business segment i.e. "Pharmaceuticals" and single reportable geographical segment i.e. "Within India".
- 3 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2016, the Company has for the first time adopted Ind AS with a transition date of April 1, 2015.
- 4 The format for un-audited quarterly results as prescribed in SEBI's Circular CIR/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with requirements of SEBI's circular dated July 5, 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.
- 5 **Reconciliation of Net Profit between Previous GAAP and IND AS for the quarter ended June 30, 2015**

	(Rs. in Lakhs)
Net Profit under Previous GAAP	68,56
Add/(Less) : Adjustments of	
Cost of employee share based payments	(1,71)
Actuarial loss on employee defined benefit funds recognized in Other Comprehensive Income	38
Physicians samples written off	10
Others	2
Deferred Tax on IND AS adjustments	(4)
Net Profit for the period under IND AS	67,31
Other Comprehensive Income (after Tax)	(25)
Total Comprehensive Income for the period	67,06

- 6 The Ind AS compliant corresponding figures in the previous period has not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- 7 Figures for the previous period have been regrouped/reclassified wherever considered necessary.

**For and on behalf of the Board of Directors of
Abbott India Limited**

Place : Mumbai
Date : August 26, 2016




Sachin Dharap
Director
DIN : 00785700